Takeda Announces Publication of FY2023 Annual Report on Form 20-F
Takeda Announces the Publication of its Annual Report on Form 20-F for FY2023
OSAKA, Japan, June 26, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”) on June 26, 2024. The Annual Report can be accessed on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/.
In addition, Takeda will also provide a hard copy of the Annual Report, which includes its most recent complete audited financial statements free of charge to any shareholder upon request. Please contact Takeda Investor Relations by e-mail at [email protected].
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.